Lesen Sie hier weiter... |  Drucken |  PDF

Ähnliche Artikel

• /K I L L K I L L K I L L -- Merck Serono/
• AVAiL Study Shows Longest Survival in Patients With Advanced Non-Small Cell Lung Cancer
• New Report Shows That Despite Poor Survival Rates Lung Cancer is not Prioritized in Europe
• New Data Confirms Avastin (R) as the Only Biologic to Demonstrate Overall Survival When Used First-Line in Metastatic Colorectal Cancer Patients With K-RAS (Wild-Type) Gene Status
• Tarceva(R) Delivers Benefits Across Broad Range of NSCLC Patients - Confirmed by New Data
• Die globale Lungenkrebskoalition gibt 3. jährlichen Lung Cancer Journalism Awards-Wettbewerb bekannt.
• Data Suggests Promising Overall Survival and Progression-Free Survival With VARGATEF(TM) (BIBF 1120)
• Avastin(R) Gives an Additional 4 Months of Life to Patients With one of the Most Common Types of Lung Cancer
• Study Confirms That Avastin Significantly Increases Chance of Living Without Disease Progression in Metastatic Breast Cancer
• Avastin(R) Continues to Demonstrate Long Term Survival for Patients With Metastatic Colorectal Cancer

Erbitux - RSS Nachrichten – Einfache Auswahl an RSS Newsfeeds zugreifen!

and other readers should disregard the news release& Erbitux Significantly Prolongs Survival in 1st-Line Treatment of Non-Small Cell Lung Cancer& NYSE:SRA,

Zeitarbeit Jobs Karriere - Marktplatz-zeitarbeit.de - News

should disregard the news release "Erbitux Significantly Prolongs.Survival in 1st-Line Treatment of Non-Small Cell Lung Cancer"

Stationäre Aufnahme: Merck Serono - Erfolgreicher "Kill"

Erbitux Significantly Prolongs Survival in 1st-Line Treatment of Non-Small Cell Lung Cancer in the 1st-Line Treatment of Patients With Non-Small Cell Lung

Presseportal: Merck Serono

Prolongs Survival in 1st-Line Treatment of Non-Small Cell Erbitux Significantly Prolongs Survival in 1st-Line Treatment of Non-Small Cell Lung Cancer

Erbitux Significantly Prolongs Survival in 1st-Line Treatment of Non ...

Erbitux Significantly Prolongs Survival in 1st-Line Treatment of Non-Small Cell Lung Cancer in the 1st-Line Treatment of Patients With Non-Small Cell